Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Doseology SciencesDOSEF 31 3-1 Month Momentum % is -71.57% as of Aug. 07, 2026. GuruFocus rates DOSEF with a GF Score™ of 31/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,387 Biotechnology companies, Doseology Sciences ranks worse than 97.33% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-07), Doseology Sciences's 3-1 Month Momentum % is -71.57%.
The industry rank for Doseology Sciences's 3-1 Month Momentum % or its related term are showing as below:
DOSEF's 3-1 Month Momentum % is ranked worse than 97.33% of 1387
companies
in the Biotechnology industry
Industry Median: -6.98
vs DOSEF: -71.57
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Doseology Sciences 3-1 Month Momentum % Related Terms
DOSEF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Doseology Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Doseology Sciences (DOSEF) has a 3-1 Month Momentum % of -71.57% as of Aug. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Doseology Sciences and its competitors. According to the industry distribution chart, Doseology Sciences ranks #1350 out of 1387 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Doseology Sciences' 3-1 Month Momentum % too high?
Doseology Sciences' current 3-1 Month Momentum % is -71.57%. Based on the distribution chart, Doseology Sciences ranks #1350 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Doseology Sciences has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Doseology Sciences ranks #1350 out of 1387 companies for 3-1 Month Momentum %. This places Doseology Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Doseology Sciences and its competitors. Doseology Sciences's current 3-1 Month Momentum % is -71.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.11 — trading 62.9% below its estimated fair value. The current 3-1 Month Momentum % is -71.57%. Doseology Sciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current 3-1 Month Momentum % is -71.57% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 62.9% below its estimated GF Value™ of $0.30.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
3-1 Month Momentum %: -71.57%
GF Value™: $0.30 vs. price of $0.11 (62.9% below fair value)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
31GF Score
Get the complete analysis for DOSEF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
